• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全膝关节置换术或全髋关节置换术后急性下肢深静脉血栓形成的直接口服抗凝治疗结果

Outcome of Direct Oral Anticoagulant Treatment for Acute Lower Limb Deep Venous Thrombosis After Total Knee Arthroplasty Or Total Hip Arthroplasty.

作者信息

Mochizuki Takeshi, Ikari Katsunori, Yano Koichiro, Hiroshima Ryo, Ishibashi Mina, Okazaki Ken

机构信息

a Department of Orthopedic Surgery , Kamagaya General Hospital , Kamagaya , Japan.

b Institute of Rheumatology, Tokyo Women's Medical University , Shinjuku , Japan.

出版信息

Mod Rheumatol. 2019 Jul;29(4):682-686. doi: 10.1080/14397595.2018.1504396. Epub 2018 Oct 1.

DOI:10.1080/14397595.2018.1504396
PMID:30041559
Abstract

The aim of this study was to examine the treatment outcomes of edoxaban and apixaban on deep venous thrombosis (DVT) in Japanese patients undergoing total knee arthroplasty (TKA) or total hip arthroplasty (THA). We examined 100 patients receiving edoxaban or apixaban to treat lower limb DVT. The primary efficacy outcome was defined as the disappearance of DVT at three months post-treatment. The primary safety outcome was the change in hemoglobin (Hb) value after two and seven days of treatment compared with baseline, which was the start of treatment with edoxaban or apixaban. The primary efficacy outcome occurred in 61 of the 70 patients (87.1%) in the edoxaban group and in 28 of the 30 patients (93.3%) in the apixaban group. There was no significant difference between the edoxaban and apixaban groups in the disappearance of DVT at three months ( = .497). The change in Hb value from baseline to two days post-treatment was -0.53 ± 0.98 in the edoxaban group and -0.06 ± 0.75 in the apixaban group ( = .010). At seven days post-treatment, the changes in Hb were -0.03 ± 1.60 and 0.30 ± 0.68 ( = .007) in the edoxaban and apixaban groups, respectively. Edoxaban and apixaban were equivalent in efficacy. However, apixaban was superior to edoxaban in terms of the change in Hb value. In cases of major bleeding, both edoxaban and apixaban need to be used carefully when treating DVT.

摘要

本研究旨在探讨依度沙班和阿哌沙班对接受全膝关节置换术(TKA)或全髋关节置换术(THA)的日本患者深静脉血栓形成(DVT)的治疗效果。我们研究了100例接受依度沙班或阿哌沙班治疗下肢DVT的患者。主要疗效指标定义为治疗后三个月DVT消失。主要安全性指标是治疗两天和七天后血红蛋白(Hb)值相对于基线(即依度沙班或阿哌沙班治疗开始时)的变化。依度沙班组70例患者中有61例(87.1%)出现主要疗效指标,阿哌沙班组30例患者中有28例(93.3%)出现该指标。依度沙班组和阿哌沙班组在三个月时DVT消失情况无显著差异(P = 0.497)。依度沙班组治疗后两天Hb值相对于基线的变化为-0.53±0.98,阿哌沙班组为-0.06±0.75(P = 0.010)。治疗七天后,依度沙班组和阿哌沙班组Hb的变化分别为-0.03±1.60和0.30±0.68(P = 0.007)。依度沙班和阿哌沙班疗效相当。然而,在Hb值变化方面,阿哌沙班优于依度沙班。在发生大出血的情况下,治疗DVT时依度沙班和阿哌沙班均需谨慎使用。

相似文献

1
Outcome of Direct Oral Anticoagulant Treatment for Acute Lower Limb Deep Venous Thrombosis After Total Knee Arthroplasty Or Total Hip Arthroplasty.全膝关节置换术或全髋关节置换术后急性下肢深静脉血栓形成的直接口服抗凝治疗结果
Mod Rheumatol. 2019 Jul;29(4):682-686. doi: 10.1080/14397595.2018.1504396. Epub 2018 Oct 1.
2
A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery.阿哌沙班与达比加群酯用于髋膝关节置换术后血栓预防的比较。
Arch Orthop Trauma Surg. 2017 Jun;137(6):797-803. doi: 10.1007/s00402-017-2697-8. Epub 2017 Apr 24.
3
Prothrombin time-international normalized ratio is a useful marker for edoxaban efficacy in preventing venous thromboembolism after total knee arthroplasty.凝血酶原时间-国际标准化比值是评估依度沙班预防全膝关节置换术后静脉血栓栓塞疗效的有用指标。
Eur J Orthop Surg Traumatol. 2018 Jan;28(1):103-108. doi: 10.1007/s00590-017-2018-5. Epub 2017 Aug 1.
4
Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty.阿哌沙班和利伐沙班可减少全髋关节和全膝关节置换术后的深静脉血栓形成,但不能减少其他并发症。
J Arthroplasty. 2013 Oct;28(9):1477-81. doi: 10.1016/j.arth.2013.02.016. Epub 2013 Mar 26.
5
The safety and efficacy of NOACs versus LMWH for thromboprophylaxis after THA or TKA: A systemic review and meta-analysis.NOACs 与 LMWH 用于 THA 或 TKA 后血栓预防的安全性和有效性:系统评价和荟萃分析。
Asian J Surg. 2024 Oct;47(10):4260-4270. doi: 10.1016/j.asjsur.2024.02.113. Epub 2024 Mar 4.
6
Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.阿哌沙班与依诺肝素预防全膝关节置换术后静脉血栓栓塞:单中心、单外科医生、回顾性分析。
Intern Med J. 2016 Sep;46(9):1030-7. doi: 10.1111/imj.13139.
7
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.依度沙班预防择期全髋关节置换术后血栓栓塞的口服直接因子 Xa 抑制:一项随机、双盲、剂量反应研究。
Thromb Haemost. 2010 Sep;104(3):642-9. doi: 10.1160/TH10-02-0142. Epub 2010 Jun 29.
8
A prospective randomized comparative study to determine appropriate edoxaban administration period, to prevent deep vein thromboembolism in patients with total knee arthroplasty.一项前瞻性随机对照研究,以确定利伐沙班的合适给药期,预防全膝关节置换术患者深静脉血栓形成。
J Orthop Sci. 2018 Nov;23(6):1005-1010. doi: 10.1016/j.jos.2018.06.004. Epub 2018 Jul 4.
9
Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.口服Xa因子抑制剂依度沙班与依诺肝素在全膝关节置换术后预防血栓形成方面的安全性和有效性:STARS E-3试验
Thromb Res. 2014 Dec;134(6):1198-204. doi: 10.1016/j.thromres.2014.09.011. Epub 2014 Sep 21.
10
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.直接Xa因子抑制剂(利伐沙班和阿哌沙班)与依诺肝素用于全膝关节置换术后预防静脉血栓栓塞:6项随机临床试验的荟萃分析
Thromb Res. 2015 May;135(5):816-22. doi: 10.1016/j.thromres.2015.02.008. Epub 2015 Feb 12.

引用本文的文献

1
Comparing residual thrombosis and venous thromboembolism outcomes between patients treated with or without anticoagulant therapy for acute distal lower-limb deep vein thrombosis after total hip arthroplasty.比较全髋关节置换术后急性下肢远端深静脉血栓形成患者接受或未接受抗凝治疗的残余血栓形成和静脉血栓栓塞结局。
Eur J Orthop Surg Traumatol. 2025 Apr 25;35(1):167. doi: 10.1007/s00590-025-04291-8.
2
Predictive value of miR-374a-5p of peripheral blood mononuclear cells in deep venous thrombosis for elderly patients after total hip arthroplasty.外周血单个核细胞miR-374a-5p对老年全髋关节置换术后深静脉血栓形成的预测价值
Am J Transl Res. 2021 Sep 15;13(9):10670-10675. eCollection 2021.
3
Does Prophylactic Administration of Edoxaban Increase D-Dimer Levels after Total Hip Arthroplasty?
预防性使用依度沙班是否会增加全髋关节置换术后的D-二聚体水平?
J Clin Med. 2019 May 14;8(5):678. doi: 10.3390/jcm8050678.